We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.
概要
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
- ウェブサイト
-
https://www.takeda.com/
Takedaの外部リンク
- 業種
- 医薬品製造業
- 会社規模
- 社員 10,001名以上
- 本社
- Tokyo
- 種類
- 上場企業
- 創立
- 1781
- 専門分野
- Pharmaceuticals、Therapeutics、Oncology、Gastroenterology、Vaccines
場所
Takedaの社員
アップデート
-
We are committed to advancing #psoriasis research and ensuring diversity within our clinical trials, as we strive toward better care and treatment outcomes for all. Takeda does not have any approved treatment for psoriasis. Please consult your healthcare provider for medical advice.
-
We're honored to be ranked among the 2024 World's Most Sustainable Companies, according to TIME and Statista. They held leaders to high standards for climate action, from the use of renewable energy to product packaging, as well as for positive social impacts and transparency. It's also heartening to see some of our peers, suppliers and partners recognized, a group we hope will continue to grow as we continue to recognize the link between climate change and human health. Learn more about how we're advancing our environmental sustainability commitment and net-zero roadmap: https://lnkd.in/e5bb7vkw #Sustainability #NetZero #ClimateAction #SocialImpact
-
What can internal mobility at a global company look like? Doug Coffman started in Clinical Data Management, moved to Global Patient Safety Evalutation, and is now building a new group in Regions & Business Operations. There are a few underlying themes to Doug’s time with us: passion and purpose lead to growth; it's possible to turn dreams into reality on a global scale; and through community and collaboration, you can shape a meaningful legacy. Read more about Doug’s journey: https://lnkd.in/emJN38mY #CareersInPharma
-
Do you know up to what percentage of people with #psoriasis are likely to develop #PsoriaticArthritis? Watch to reveal the correct answer. Early diagnosis and treatment can help limit joint damage from #PsoriaticArthritis. Takeda does not have any approved treatment for psoriasis. Please consult your healthcare provider for medical advice.
-
Recently, we joined the United Nations Institute for Training and Research (UNITAR) in hosting a roundtable with representatives from the global healthcare and patient communities to discuss the role of plasma-derived therapies in global healthcare and the need to urgently tackle barriers to plasma products worldwide. Learn more about this important discussion by watching the roundtable: https://lnkd.in/dexAvefU
Plasma4Life: Bridging the Gap in Access to Plasma and Plasma-derived Medicinal Products
https://www.youtube.com/
-
Rick Ascroft, head of the U.S. Plasma-Derived Therapies Business Unit, sheds light on the reality of patients living with chronic inflammatory demyelinating polyneuropathy (#CIDP), discusses Takeda’s rich history in plasma and shares insights into better supporting people living with CIDP. Read more about CIDP and the work we do to support patients with this illness. https://lnkd.in/ehkeQwiC
-
We're focused on driving meaningful dialogues with industry experts about the future of AI in health care. Julie Kim, President of U.S. Business Unit and U.S. Country Head, shares why data is key to harnessing AI's potential to improve the patient journey and other insights she learned from thought leaders at #AspenIdeasHealth.
During a recent convening of thought leaders from across the health care industry, we discussed the future of AI in health care. While many common themes emerged, one thing was clear from our discussion – there are still many questions and a lot of work to be done in collaboration with one another if we are to achieve a future state in which AI can benefit patients, be an important companion to HCPs and help scientists deliver medicines faster while safeguarding against unintended harm. Read more about a few of the key takeaways here.
-
Last week, we tested your knowledge on the guidelines-based standard of care for treating #CIDP (chronic inflammatory demyelinating polyneuropathy), a chronic, progressive condition that may require long-term management. 70% of you picked the correct answer – there are several guidelines-based treatment options for CIDP: corticosteroids, immunoglobulins, and plasmapheresis. The path to diagnosis and treatment can be a long process for people living with CIDP. We’re committed to doing our part for patients and moving science forward. Learn more: https://lnkd.in/eM_9wmRe
-
We leave the #IFPAConference2024 inspired by the resilience of those in the psoriasis and psoriatic arthritis communities. Our dedication to making a difference in patients’ lives is stronger than ever. Thank you to IFPA for bringing the community together for this incredible event. This information is for IFPA conference attendees only. It should never be used as a substitute for the advice provided by your healthcare provider. Please consult with your healthcare provider for medical advice. Takeda does not have any approved treatment for psoriasis or psoriatic arthritis.